keyword
MENU ▼
Read by QxMD icon Read
search

memantine bpsd

keyword
https://www.readbyqxmd.com/read/27651011/pharmacological-treatments-of-behavioral-and-psychological-symptoms-of-dementia-in-alzheimer-s-disease-role-of-acetylcholinesterase-inhibitors-and-memantine
#1
Thomas Desmidt, Caroline Hommet, Vincent Camus
Behavioral and psychological symptoms of dementia (BPSD) are frequent in Alzheimer's disease (AD). They are associated with disability and suffering for both the patients and their caregivers. Even if BPSD are now well diagnosed and characterized by standardized tools, their treatment remains often challenging in clinical setting because of the frequent and severe side effects of the psychotropic drugs when used in this indication. Evidence-based data confirm that antipsychotics and antidepressants are efficient for the treatment of BPSD but have a poor tolerance profile and their use is problematic...
September 1, 2016: Gériatrie et Psychologie Neuropsychiatrie du Vieillissement
https://www.readbyqxmd.com/read/26401570/clinical-benefits-of-memantine-treatment-for-alzheimer-s-disease-in-the-okayama-memantine-study-ii-oms-ii
#2
Kosuke Matsuzono, Toru Yamashita, Yasuyuki Ohta, Nozomi Hishikawa, Makoto Koike, Kota Sato, Syoichiro Kono, Kentaro Deguchi, Yumiko Nakano, Koji Abe
The clinical benefits of memantine, depending on the baseline cognitive and affective conditions in real world dementia clinics, have not been completely examined. We performed the "Okayama Memantine Study II (OMS II)" to retrospectively evaluate the clinical effects of memantine monotherapy (n = 38) in Alzheimer's disease (AD) patients using seven batteries to assess dementia at the baseline, at 3, 6, and 12 months. Additionally, we divided 163 AD patients treated with memantine into two subgroups depending on the baseline cognitive score of the Mini-Mental State Examination (MMSE): the MMSE <15 group (n = 36) and the baseline MMSE ≥15 group (n = 127)...
2015: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/26090082/effect-of-rivastigmine-on-behavioral-and-psychiatric-symptoms-of-parkinson-s-disease-dementia
#3
Yoon-Sang Oh, Joong-Seok Kim, Phil Hyu Lee
OBJECTIVE: A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer's dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine is efficacious for the treatment of dementia in Parkinson's disease (PD). We investigated the efficacy of rivastigmine for BPSD in patients with Parkinson's disease dementia (PDD). METHODS: Twenty-three patients in whom cognitive impairment occurred at least one year after a diagnosis of PD participated in this open-label trial...
May 2015: Journal of Movement Disorders
https://www.readbyqxmd.com/read/25141581/-pharmacological-treatment-of-behavioral-symptoms-in-dementia-patients
#4
REVIEW
Tomasz Gabryelewicz
Cognitive manifestations usually are the primary abnormalities in dementia. In most cases cognitive deterioration arise in association with behavioral disturbances, and may accelerate institutionalization of patients. Noncognitive symptoms are distressing for both patients and their caregivers. These symptoms are described as "behavioral and psychological symptoms of dementia--BPSD" or neuropsychiatric symptoms. BPSD occurs in all types of dementia, and often are among the most prominent symptoms in the clinical course of the disease...
2014: Przegla̧d Lekarski
https://www.readbyqxmd.com/read/24278094/responsiveness-of-the-qualid-to-improved-neuropsychiatric-symptoms-in-patients-with-alzheimer-s-disease
#5
Hadas Benhabib, Krista L Lanctôt, Goran M Eryavec, Abby Li, Nathan Herrmann
BACKGROUND: This study aimed to determine whether the Quality of Life in Late-Stage Dementia (QUALID) scale is responsive to changes in behaviour due to therapeutic intervention. METHOD: 31 long-term care residents with moderate to severe AD and agitation/aggression entered a three-month, open-label trial of memantine 10 mg BID. The relationships between the QUALID and BPSD, global improvement, and cognition at baseline and endpoint, as well as the changes in these scales as a result of treatment, were examined...
2013: Canadian Geriatrics Journal: CGJ
https://www.readbyqxmd.com/read/24167684/clinical-efficacy-and-changes-in-the-dosages-of-concomitantly-used-psychotropic-drugs-in-memantine-therapy-in-alzheimer-s-disease-with-behavioral-and-psychological-symptoms-on-dementia
#6
Hidenobu Suzuki, Yuichi Inoue, Akiyoshi Nishiyama, Katsunaka Mikami, Keishi Gen
OBJECTIVE: We investigated the clinical efficacy and changes in the dosages of concomitantly used psychotropic drugs in memantine therapy in Alzheimer's disease (AD) with behavioral and psychological symptoms on dementia (BPSD). METHODS: The subjects were 38 inpatients who had been diagnosed with AD according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). The outcome measures assessed were BPSD and cognitive function. BPSD was assessed using the neuropsychiatric inventory (NPI) and cognitive function was assessed using the mini-mental examination (MMSE)...
June 2013: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/24164733/differential-effects-of-current-specific-treatments-on-behavioral-and-psychological-symptoms-in-patients-with-alzheimer-s-disease-a-12-month-randomized-open-label-trial
#7
RANDOMIZED CONTROLLED TRIAL
Eduardo Cumbo, Leonarda Domenica Ligori
BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) occur in up to 80% of Alzheimer's disease (AD) patients and represent one of the most common reasons for early institutionalization and increase in management costs. OBJECTIVES: This study evaluated the effects of four drugs (memantine, donepezil, rivastigmine, galantamine) in BPSD in AD patients. METHODS: This was a prospective, longitudinal, randomized, open-label, 4-arm, parallel-group, 12-month clinical trial carried out in 177 AD patients...
2014: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/23691791/-effectiveness-and-limitation-of-newly-approved-drugs-for-alzheimer-s-disease
#8
REVIEW
Hideyuki Hattori
Galantamine, rivastigmine, and memantine, for the treatment of Alzheimer-type dementia, became covered by national health insurance last year in Japan. Galantamine and rivastigmine are choline esterase inhibitors, and memantine is a glutamate NMDA receptor antagonist. Galantamine also acts on the nicotinic acetylcholine receptor, in addition to ChEI, and it has an APL action and modulates the receptor function by inducing a structural change of the receptor, as its characteristics. Rivastigmine is used only in patch form, and exhibits an inhibitory effect on butyryl choline esterase...
2013: Seishin Shinkeigaku Zasshi, Psychiatria et Neurologia Japonica
https://www.readbyqxmd.com/read/23450042/nmda-neurotransmission-dysfunction-in-behavioral-and-psychological-symptoms-of-alzheimer-s-disease
#9
Yu-Jhen Huang, Chieh-Hsin Lin, Hsien-Yuan Lane, Guochuan E Tsai
Dementia has become an all-important disease because the population is aging rapidly and the cost of health care associated with dementia is ever increasing. In addition to cognitive function impairment, associated behavioral and psychological symptoms of dementia (BPSD) worsen patient's quality of life and increase caregiver's burden. Alzheimer's disease is the most common type of dementia and both behavioral disturbance and cognitive impairment of Alzheimer's disease are thought to be associated with the N-methyl-D-aspartate (NMDA) dysfunction as increasing evidence of dysfunctional glutamatergic neurotransmission had been reported in behavioral changes and cognitive decline in Alzheimer's disease...
September 2012: Current Neuropharmacology
https://www.readbyqxmd.com/read/23293526/two-cases-of-alzheimer-s-disease-showing-deterioration-of-behavioral-and-psychological-symptoms-of-dementia-induced-by-switching-from-rivastigmine-to-donepezil
#10
Takemi Kimura, Junichi Takamatsu
Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years, have been available for the treatment of Alzheimer's disease (AD) since 2011 in Japan, leading a new stage in the medical treatment of AD. We studied two AD patients showing sudden deterioration of behavioral and psychological symptoms of dementia (BPSD) associated with switching from rivastigmine to donepezil after the clinical trial of rivastigmine. In the patients, rivastigmine seemed to be more beneficial than donepezil for the control of BPSD...
2013: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/22350526/does-pharmacological-treatment-of-neuropsychiatric-symptoms-in-alzheimer-s-disease-relieve-caregiver-burden
#11
REVIEW
Karen Levy, Krista L Lanctôt, Shale B Farber, Abby Li, Nathan Herrmann
Caregiving for patients with Alzheimer's disease (AD) is associated with negative outcomes for the caregiver such as depression, anxiety, medical illness, poorer general health and mortality, which further translate into adverse outcomes for the patient. The burden experienced by caregivers of AD patients, both professional and informal, has been found to be positively related to the presence and severity of the patients' neuropsychiatric symptoms, also referred to as the behavioural and psychological symptoms of dementia (BPSD)...
March 1, 2012: Drugs & Aging
https://www.readbyqxmd.com/read/22328204/treatment-of-behavioral-and-psychological-symptoms-of-alzheimer-s-disease
#12
Anne Corbett, Jessica Smith, Byron Creese, Clive Ballard
Behavioral and psychological symptoms of dementia (BPSD) are frequent amongst people with Alzheimer's disease (AD) and other dementias, commonly confer risk to that person and others, and present a significant management challenge for clinicians. There is increasing evidence to support the value of simple psychological interventions and the treatment of pain as a first-line management strategy prior to pharmacotherapy. The most widely prescribed pharmacological treatments-atypical antipsychotics-have a modest but significant beneficial effect in the short-term treatment of aggression (over 6-12 weeks) but limited benefits in longer-term therapy...
April 2012: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/22163246/the-efficacy-of-licensed-indication-use-of-donepezil-and-memantine-monotherapies-for-treating-behavioural-and-psychological-symptoms-of-dementia-in-patients-with-alzheimer-s-disease-systematic-review-and-meta-analysis
#13
I A Lockhart, M E Orme, S A Mitchell
BACKGROUND/AIMS: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. METHODS: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. RESULTS: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis...
January 2011: Dementia and Geriatric Cognitive Disorders Extra
https://www.readbyqxmd.com/read/22039732/-treatment-of-behavioral-disorders-in-alzheimer-s-disease
#14
Renaud David, Julie Piano, Philippe Robert
Behavioural and psychological symptoms (BPSD) are now known to be frequently associated to cognitive and functional decline in Alzheimer's disease and related disorders. Recommendations for the management of BPSD have been proposed. Non-pharmacological interventions should be the first-line treatment. Anti-dementia agents (cholinesterase inhibitors, memantine) and psychotropic drugs (antipsychotics, antidepressants and anticonvulsivants) could be associated to non-pharmacological interventions only in case of limited response with non pharmacologic approaches...
September 2011: La Revue du Praticien
https://www.readbyqxmd.com/read/21934621/pharmacological-treatment-of-dementia-and-mild-cognitive-impairment-due-to-alzheimer-s-disease
#15
REVIEW
Julius Popp, Sönke Arlt
PURPOSE OF REVIEW: To give an overview of recent developments in pharmacological treatment options of cognitive as well as behavioural and psychological symptoms of dementia (BPSD) associated with Alzheimer's disease (AD) dementia and mild cognitive impairment due to AD (MCI-AD). RECENT FINDINGS: Knowledge about the efficacy and limitations of the antidementive drugs memantine and cholinesterase inhibitors (ChEIs) in different stages of AD is further expanding. The prediction of treatment response to ChEI and assessment of treatment outcome in the individual patient remain unsolved issues...
November 2011: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/21584738/memantine-effects-on-behaviour-in-moderately-severe-to-severe-alzheimer-s-disease-a-post-marketing-surveillance-study
#16
Francesca Clerici, Nicola Vanacore, Antonietta Elia, Stefania Spila-Alegiani, Simone Pomati, Roberto Da Cas, Roberto Raschetti, Claudio Mariani
The aim of this study is to evaluate memantine effectiveness on behavioural and psychological symptoms of dementia (BPSD) in clinical practice and to identify variables that may predict the therapy effects. The effects of memantine on behaviour were analysed in the database of a post-marketing surveillance study promoted by the Lombardy Region Health Office and involving 43 Alzheimer's disease (AD) Units. From July to December 2005, 399 moderately severe-to-severe AD patients free of cholinergic medications were enrolled, treated with memantine and followed-up for 6 months...
February 2012: Neurological Sciences
https://www.readbyqxmd.com/read/21189108/pharmacological-treatment-of-behavioural-and-psychological-symptoms-of-dementia-in-psychogeriatric-inpatient-units
#17
Sam Restifo, Vivienne Lemon, Flavie Waters
OBJECTIVE: This study involved an examination of the current patterns of pharmacological treatment of patients with behavioural and psychological symptoms of dementia (BPSD) in psychogeriatric inpatient units. METHOD: An audit was conducted of discharge medications of patients with BPSD who were hospitalized at three separate inpatient units in Perth, Western Australia over a 1-year period. RESULTS: Prescribing patterns were found to be relatively similar across the three units...
February 2011: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/20675883/-development-of-new-drugs-for-alzheimer-s-disease
#18
REVIEW
Takeshi Tabira
Currently, only donepezil is available for the treatment of Alzheimer disease (AD) in Japan. Clinical trials of galantamine, rivastigmine, and memantine have been completed in Japan, and patients are awaiting government approval for the use of these drugs. The herbal medicine yokukansan was found to be effective for behavioral and psychological symptoms of dementia (BPSD) in patients, and juzentaihoto was found to reduce AD pathology in a mouse model. In addition, muscarinic and nicotinic acetylcholine receptor agonists, serotonergic agonists, other drugs are being developed...
July 2010: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/19696673/management-of-agitation-and-aggression-associated-with-alzheimer-s-disease-controversies-and-possible-solutions
#19
REVIEW
Clive Ballard, Anne Corbett, Ramilgan Chitramohan, Das Aarsland
PURPOSE OF REVIEW: Behavioral and psychological symptoms of dementia (BPSD) are frequent among people with Alzheimer's disease and other dementias, commonly confer risk to the person and others, and present a significant management challenge for clinicians. The purpose of this review is to describe the current state of knowledge regarding management of BPSD, with a particular focus on agitation. RECENT FINDINGS: There is increasing evidence to support the value of simple psychological interventions and staff-training programs as a first-line management strategy for agitation prior to pharmacotherapy...
November 2009: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/19488082/management-of-agitation-and-aggression-associated-with-alzheimer-disease
#20
REVIEW
Clive G Ballard, Serge Gauthier, Jeffrey L Cummings, Henry Brodaty, George T Grossberg, Philippe Robert, Constantine G Lyketsos
Agitation and aggression are frequently occurring and distressing behavioral and psychological symptoms of dementia (BPSD). These symptoms are disturbing for individuals with Alzheimer disease, commonly confer risk to the patient and others, and present a major management challenge for clinicians. The most widely prescribed pharmacological treatments for these symptoms-atypical antipsychotics-have a modest but significant beneficial effect in the short-term treatment (over 6-12 weeks) of aggression but limited benefits in longer term therapy...
May 2009: Nature Reviews. Neurology
keyword
keyword
80515
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"